Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $3.0 million.

  • Utah Medical Products' Total Current Liabilities fell 1234.35% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 1234.35%. This contributed to the annual value of $3.8 million for FY2024, which is 2023.35% down from last year.
  • Utah Medical Products' Total Current Liabilities amounted to $3.0 million in Q3 2025, which was down 1234.35% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' Total Current Liabilities registered a high of $6.3 million during Q3 2022, and its lowest value of $2.3 million during Q2 2025.
  • In the last 5 years, Utah Medical Products' Total Current Liabilities had a median value of $4.4 million in 2022 and averaged $4.6 million.
  • In the last 5 years, Utah Medical Products' Total Current Liabilities soared by 5914.55% in 2022 and then crashed by 4277.74% in 2025.
  • Utah Medical Products' Total Current Liabilities (Quarter) stood at $3.7 million in 2021, then soared by 59.15% to $6.0 million in 2022, then fell by 20.97% to $4.7 million in 2023, then fell by 20.23% to $3.8 million in 2024, then dropped by 19.86% to $3.0 million in 2025.
  • Its Total Current Liabilities was $3.0 million in Q3 2025, compared to $2.3 million in Q2 2025 and $4.3 million in Q1 2025.